Recommendations for the Development of Rare Disease Drugs using the Accelerated Approval Pathway and for Qualifying Biomarkers as Primary Endpoints in Pivotal Clinical Studies
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.